Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 9Capecitabine 7durvalumab 6pembrolizumab 4tremelimumab 3S 1 (combination) 3Nivolumab 3AZD 6244 3Ramucirumab 2Fluorouracil 2130-nm albumin-bound paclitaxel 2vandetanib 1trifluridine tipiracil drug combination 1trametinib 1tocilizumab 1titanium silicide 1sacituzumab govitecan 1poly ICLC 1futibatinib 1fludarabine 1cemiplimab 1binimetinib 1aflibercept 1Tegafur 1TAS-116 1Psilocybin 1Peptides 1Oxaliplatin 1NUC-1031 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Biliary Tract Neoplasms × Antibodies × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡